Recent Press Releases

Allergan, Inc. Announces the JUVEDERM(R) 'Switch Up' Campaign Educating Women on the Positive Impact Small Changes Have on Personal Appearance  

BOTOX^® (OnabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults  

Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine  

Allergan Celebrates 20 Years of Approved Use of Botulinum Toxin Type A (BOTOX(R)) in Canada  

Allergan Reports Fourth Quarter 2009 Operating Results  

Allergan, Inc. Announces FDA Approval of JUVÉDERM(R) XC Dermal Filler Formulated with Lidocaine  

Allergan Announces Quarterly Conference Call  

Nationwide Survey Shows Americans Oppose Cosmetic Tax to Pay for Health Care Reform  

Allergan Reports Third Quarter 2009 Operating Results  

Allergan Announces Victory in Brimonidine Patent Infringement Case  

Allergan Files Federal Lawsuit to Allow It to Share Relevant Information with the Medical Community on the Safe Use of BOTOX(R) for Common Therapeutic Off-Label Treatments  

Allergan Announces Quarterly Conference Call  

Quintiles and Allergan Announce Co-Promotion for Sanctura XR(R)  

Allergan Reports Second Quarter 2009 Operating Results  

Allergan Receives FDA Approval for ACUVAIL(TM) Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery  

FDA Designates Fast Track Status for Apaziquone (EOquin(R)) for Bladder Cancer  

Allergan Announces Quarterly Conference Call  

Allergan Receives FDA Approval for OZURDEX^™ Biodegradable, Injectable Steroid Implant with Extended Drug Release for Retinal Disease  

Allergan Receives Complete Response Letter for BOTOX(R) (Botulinum Toxin Type A) for Treatment of Upper Limb Spasticity in Adults  

VIDEO: Allergan, Inc. Announces the 'BOTOX(R) Cosmetic: Express Success' Charitable Education Campaign, Committing $250,000 to the Not-For-Profit Dress for Success